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etin formation at continuous hypoxia is not due to feedback 
inhibition. Am. J. Physiol. 258 (Renal Fluid Electrolyte Physiol. 
27): F1432-F1437,1990.- Serum erythropoietin (EPO) levels 
in response to hypoxia are known to decline before an increase 
in blood oxygen carrying capacity. To define the possible mech- 
anisms underlying this phenomenon, we have investigated 1) 
how renal EPO mRNA content and EPO production rate 
underlying the early kinetics of serum EPO levels change under 
different degrees of normobaric hypoxia, and 2) if a feedback 
inhibition of either EPO formation or EPO survival in the 
circulation exists by the hormone itself. We found that serum 
immunoreactive EPO levels in rats peaked after 12-h exposure 
to 7.5 or 9% oxygen (2,949 & 600 and 756 * 108 mu/ml, 
respectively, mean & SE) and declined to 29 and 64% of peak 
levels, respectively, after 36 h of hypoxia. EPO levels in re- 
sponse to 11.5% oxygen showed no consistent change between 
12 (122 & 21 mu/ml, mean & SE) and 36 h (182 $I 35 mu/ml) 
of hypoxia. The decline in EPO levels under severe hypoxia 
(7.5% 02) was paralleled by a marked reduction in renal EPO 
mRNA content, indicating that it was primarily a result of 
diminished hormone production. The observed reductions in 
serum EPO after 36 h corresponded to preceding declines of 
calculated EPO production rates from 163- to 62-fold (7.5% 
02) and 36- to 25-fold (9% 02) basal values. Application of 50 
IU recombinant human EPO to rats 12 h, 6 h, or immediately 
before hypoxic exposure to mimic the early increase in EPO 
levels did not affect endogenous EPO formation during a sub- 
sequent hypoxic exposure of 12 h. These results indicate that 
the early decrease in EPO production at continuous hypoxia is 
not mediated by a negative feedback control through the effect 
of EPO on its production sites or target cells. Although the 
reduction in EPO production rate occurs independent of the 
amount of EPO produced, the magnitude of the decline appears 
to be related to the degree of the preceding stimulation. 
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TO ADAPT RED CELL MASS to oxygen demand of the 
organism, the glycoprotein hormone erythropoietin 
(EPO) is produced by the kidneys in inverse correlation 
with the oxygen content of arterial blood. Following 
acute hypoxic hypoxia, an increase in renal EPO mRNA 
has been demonstrated after 1 h (27), and circulating 
EPO increases within 1.5-2 h (27). Interestingly, it has 
been demonstrated that EPO levels reach maximal val- 
ues after 6-24 h in rodents (1, 5, 15, 17, 20, 22, 26, 31) 
and within 48 h in humans (1,24) and thereafter decline 
despite continued hypoxia. This early decrease in EPO 
levels occurs before red cell mass and therewith blood 
oxygen content has increased significantly (1,17,20,26). 
The mechanisms of this early decline have not been 
clarified but several hypotheses have been developed. 
Because circulating EPO levels are determined by the 
production rate and the clearance rate of the hormone, 
possible alterations in both have to be considered. One 
concept has early been proposed suggesting that EPO 
consumption might be increased by activated erythro- 
poietic tissue (31). This has been supported by some 
clearance studies (21, 25) but others found no difference 
in EPO clearance rate in animals with hypo- or hyper- 
plastic bone marrow (23) or any change in clearance rate 
after hypoxia (13). Alternatively, the proliferating ery- 
thron might also exert a feedback inhibition on EPO 
production by mechanisms that would have to be inde- 
pendent of circulating red cell mass. Support for this 
concept comes from observations suggesting that EPO 
titers are higher in patients with bone marrow hypoplasia 
than in comparably anemic patients with active eryth- 
ropoiesis (9, 28). Other factors that were considered to 
possibly reduce EPO production independent of eryth- 
roid stimulation include a lowered blood oxygen affinity 
at prolonged hypoxia due to acidosis (8, 20, 26, 32) and 
malnutrition during continuous hypoxic stress. The lat- 
ter appears, however, not to be the primary mechanism 
because EPO titers in fed and food-deprived rats were 
found to increase similarly on repeated hypoxia exposure 
(18). A further possibility is that EPO production is 
reduced as a result of a direct feedback inhibition through 
the hormone itself. 
The present study in rats was therefore performed to 
address some of these possibilities and confine the po- 
tential mechanisms by which the early decline in EPO 
levels is brought about. First we tested whether the 
reduction of EPO levels is primarily caused by reduced 
hormone production. Because renal EPO production is 
determined by the amount of EPO mRNA (4, 27), we 
have compared the amounts of renal EPO mRNA before 
and after peak levels of serum EPO had been reached. 
Second, we examined whether EPO itself exerts a feed- 
back inhibition, either through stimulation of the ery- 
thron or a direct effect on its production sites. The effect 
of circulating EPO on its own production and secretion 
has, to our knowledge, so far only been addressed by 
Fried and co-workers (13, 14). In some (l3), but not all 
of their experiments (14), plasma erythropoietic bioac- 
tivity in rats that were both made hypoxic and injected 
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with EPO approximated the sum of that in animals that 
received EPO only and that in animals made hypoxic 
without receiving exogenous EPO. However, in these 
studies EPO was administered for no longer than 3 h 
before the onset of hypoxia, and animals were then 
exposed to continuous hypoxia for only 3 h. Because 
EPO levels have mainly been reported to decline 18 h or 
later after onset of hypoxia (1,5, 17, 20,22), this chosen 
time interval might have been too short to see an effect 
that could account for the reduction of EPO levels nor- 
mally occurring under continuous hypoxia. In this study 
we injected rats with recombinant human EPO (rhEP0) 
either 12 h, 6 h, or immediately before a hypoxic exposure 
of 12 h to mimic the early increase in EPO levels and 
compared the endogenous EPO production following the 
hypoxia with that in untreated animals. Finally, we 
estimated the kinetics of EPO production rates under- 
lying the changes in serum EPO levels and related alter- 
ations in the production rate to the degree of hypoxia. 
Our findings indicate that the decline in serum EPO 
levels results primarily from a decrease in EPO produc- 
tion rate. This decrease appears not to be mediated by 
the hormone itself and occurs independently of the 
amount of EPO produced, whereas the rate of decline 
seems to be related to the degree of the preceding stim- 
ulation. 
MATERIALS AND METHODS 
Animals. Zur:SIV strain male rats (body wt 250-300 
g) were used in this study. 
Hypoxic stimulation of EPO production. Normobaric 
arterial hypoxia was used as stimulus for EPO formation. 
To this end animals were exposed to an atmosphere low 
in oxygen (7.5,9, and 11.5% 02) with the use of a chamber 
gassed with appropriate mixtures of normal air and ni- 
trogen. Groups of five to seven animals were simultane- 
ously exposed to hypoxia for varying time periods from 
3 to 36 h. At the onset of hypoxia the chamber was 
flushed to achieve the respective oxygen tensions within 
-25 min. Oxygen content of the gas mixture in the 
chamber was checked by means of a Bacharach Fyrite 
oxygen indicator (Bacharach, Pittsburgh, PA). 
Within 15 min after the end of hypoxic exposure 
animals were bled from the dorsal aorta under ether 
anesthesia for determination of serum EPO levels. 
Experiments with exogenous application of EPO. To 
assess the importance of circulating EPO for the early 
decline in serum EPO levels under continuous hypoxia 
(see RESULTS), rhEP0 was administered to rats 12 h, 6 
h, or immediately before a subsequent hypoxic exposure 
of 12 h (7.5% 02). Fifty international units rhEP0 were 
dissolved in saline and injected via a tail vein under light 
methofane anesthesia. Control animals were injected 
with saline only and simultaneously exposed to hypoxia. 
To estimate the amount of residual rhEP0 in serum 
after the end of the hypoxic exposure, additional animals 
were injected with the same amount of rhEP0, but not 
exposed to hypoxia, and bled 12, 18, and 24 h after the 
injection. 
Determination of EPO clearance rate. Calculation of 
EPO production rates from the change in serum EPO 
levels requires an estimate of EPO clearance rate. To 
determine the disappearance rate of homologous EPO in 
the rat, clearance studies were carried out in three ani- 
mals. After anesthesia with 100 mg/kg body wt 5-ethyl- 
5-( 1 ‘-methylpropyl)-2-thiobarbituric acid (Inactin, Byk- 
Gulden, Constance, FRG), these animals were art&ally 
ventilated by means of a Harvard small animal respirator 
(25% 02, 75 strokes/min, stroke volume 2 ml) to avoid 
hypoxic stimulation of endogenous EPO formation. 
EPO-enriched rat serum containing 3,500 mU immuno- 
reactive (ir) EPO/ml was obtained from hypoxic donor 
animals and injected intravenously via a femoral catheter 
at a dose of 20 U EPO/kg body wt. Before, 2 min after, 
and at subsequent hourly intervals after the injection, 
150 ~1 of blood were withdrawn from a catheter in the 
femoral artery for determination of serum EPO (see 
below). 
Figure 1 demonstrates the decline in serum irEP 
values. One hour following the administration, values 
fitted a single exponential regression curve: log serum 
irEP (mu/ml) = -0.0027 X time (min) + 2.36 (r = 
-0.94). The half-life time of disappearance resulting 
from this slope is 110 min. This value is in accordance 
with a previous study, estimating an elimination half- 
life of 86 min from the decline of serum levels within 2 
h after application of homologous EPO to rats (30) and 
more recent investigations, determining the elimination 
half-life of iodinated rhEP0 in the rat between 108 (16) 
and 180 min (29). To assess whether the clearance rate 
of EPO is different in normoxic and hypoxic animals, 
the recovery of intravenously injected iodinated rhEP0 
( 1251-rhEPO) (Amersham International, Buckingham- 
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FIG. 1. Serum clearance of irEP in 3 rats injected with homologous 
EPO at a concentration of 20 U/kg body wt. The individual basal value 
was subtracted from the serum value. After 1 h, values fitted a single 
exponential regression line: log serum irEP (mu/ml) = -0.0027 x 
time (min) + 2.36, r = -0.94. The resulting tl/, is 110 min. 
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hypoxia was compared. Under light methofane anes- 
thesia 10 rats were injected via a tail vein with 120,650 
counts/min (cpm) of 1251-EP0 (sp act, 710 Ci/mmol) 
dissolved in 0.9% NaCl containing 0.1% bovine serum 
albumin. Five animals each were then immediately ex- 
posed to hypoxia (7.5% 02) for 5 h or kept at room 
atmosphere. Five hours fifteen minutes after the injec- 
tion, animals in both groups were bled from the dorsal 
aorta for determinations of residual radioactivity. Table 
1 illustrates that no evidence was obtained for a change 
of EPO clearance rate under hypoxia. 
Determination of EPO. EPO was determined by radio- 
immunoassay as previously described (11) with the use 
of an antiserum raised against rhEP0 and ‘*‘I-rhEP0 as 
tracer. The antiserum is cross-reactive with rat EPO but 
displacement curves for rat and human EPO are differ- 
ent. Therefore different standard preparations were used 
to determine human or rat EPO concentrations. 1) Serial 
dilutions of a rat serum pool, enriched in EPO by expos- 
ing donor animals to hypoxia, were used as standards for 
determinations of rat EPO. This serum pool was previ- 
ously calibrated against the Second International Ref- 
erence Preparation (II-IRP, World Health Organization) 
in the polycythemic mouse bioassay (11). 2) In those 
assays designed to estimate the amount of human EPO 
after injection of rhEP0 to rats, the standard curve 
consisted of standard amounts of human EPO (II-IRP) 
that were added to normal rat serum. 3) In experiments 
carried out to determine endogenous production of rat 
EPO in hypoxic animals injected with rhEP0, the aver- 
age concentration of residual human EPO that was de- 
termined in animals injected with rhEP0 but not ex- 
posed to hypoxia was added to each standard dilution of 
the rat serum pool. 
Northern Blot Analysis 
Northern blot analysis of renal EPO mRNA was per- 
formed in normotoxic animals and animals exposed to 
7.5% O2 for 8 or 36 h. For control EPO mRNA was 
simultaneously analyzed from IW32 cells (7). 
RNA isolation. Total RNA was isolated from rat kid- 
neys or IW32 cells as described (6) and further purified 
by precipitation in a LiCl-urea-containing solution (2). 
Poly (A)’ RNA was isolated by chromatographic sepa- 
ration using oligo-(dT) cellulose spun columns (Phar- 
macia, Uppsala, Sweden) following the instructions of 
the supplier. 
TABLE 1. Recovery of 1251-rhEP0 in normoxic 
(21% 02) and hypoxic (7.5% 02) rats 5.25 h 
after intravenous injection 
02 
21% 7.5% 
Serum, cpm/ml 1,476+274 1,418+221 
Recovery of injected dose, % 13.222.4 12.7t2.0 
Values are total counts and represent mean k SE of 5 animals each. 
Activity of the injected dose was 120,650 cpm. 89% of the radioactivity 
injected and 87.9=t1.6% of the radioactivity in serum samples was acid- 
precipitable. Recovery of injected dose was calculated assuming a 
distribution volume of rhEP0 in rats that corresponds to plasma 
volume (3.93 ml/l00 g body wt) (29). 
Northern blot. RNA sample preparation and electro- 
phoresis were performed as described (12). The agarose 
concentration of the gel was 1%. After running at con- 
stant voltage (90 V) the gel was first soaked in 1 X 
standard sodium citrate (SSC) (0.15 M NaCl, 0.015 M 
sodium citrate, pH 7.0) containing 0.05 N NaOH for 10 
min before equilibration with 10 X SSC. Blotting was 
performed onto Hybond N (Amersham) for at least 18 h. 
After blotting, the filter was baked for 30 min at 80°C. 
Hybridization. The filter was rehydrated in 2 X SSC 
and prehybridized overnight at 42°C in a solution con- 
taining 50% formamide, 4 x SSC, 5 x Denhardt’s solu- 
tion (0.1% polyvinylpyrrolidone 360, 0.1% Ficoll 400, 
0.1% bovine serum albumin), 25 mM sodium phosphate 
(pH 6.5), 300 pg/ml sheared denatured salmon sperm 
DNA, and 0.1% sodium dodecyl sulfate (SDS). Three 
hundred microliters of the prehybridization solution were 
used per square centimeter filter. EPO-specific mRNA 
was detected by hybridization with pDB2-5, a plasmid 
containing the BglII-fragment of the murine EPO gene, 
inserted into the BamHI site of the plasmid vector PUC 
19. The plasmid was labeled with [32P]dCTP (Amer- 
sham) to a specific activity of -lo8 cpm/pg DNA by the 
oligo primed labeling procedure with the use of the 
multiprime kit (Amersham). After labeling, the DNA 
was purified by spun-column chromatography using 
Sephadex G-50 (Pharmacia). Hybridization was per- 
formed overnight at 42°C in the same solution as de- 
scribed for prehybridization but with 3 x Denhardt’s and 
supplemented with 10% dextran sulfate and 10 rig/ml 
labeled EPO probe. After hybridization the filter was 
washed once in 2 x SSC for 5 min at RT, once in 0.2 X 
SSC for 5 min at RT, twice in 0.1 X SSC for 15 min at 
61°C and once in 2 x SSC for 5 min at RT. To each 
solution SDS was added to a final concentration of 0.1%. 
After drying, the filter was exposed to DuPont Cronex 4 
(Du Pont de Nemours, Bad Homburg, FRG). For control, 
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RESULTS 
Figure 2, top, demonstrates the kinetics of serum 
irEP values in rats exposed to three different degrees 
of normobaric hypoxia (7.5, 9, and 11.5% 02) for up to 
36 h. Under 7.5 and 9% 02, EPO levels peaked after 12 
h of exposure and declined to 29 and 64% of these values, 
respectively, after 36 h of hypoxia. In response to 11.5% 
02, EPO values approximated a plateau between 12 and 
36 h, with no sustained reduction during this phase. 
Employing the average half-life time of 110 min, as 
determined from clearance experiments (Fig. l), the rel- 
ative production rates of EPO in response to the different 
hypoxic stimuli were calculated from serum irEP levels 
and are demonstrated in Fig. 2, bottom. It becomes ob- 
vious that the peaks in serum EPO levels are preceded 
by peak levels of the production rate by -3 h. 
To determine whether the decline in EPO levels after 
12 h of continuous hypoxia, which was most prominent 
under severe hypoxic stress (7.5% OJ, might be induced 
by the previous increase in EPO levels, rhEP0 was 
administered to rats at different times before the hypoxic 
exposure. Because the distribution volume of human 
EPO in rats has been found to correspond to plasma 
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FIG. 2. Time-dependent change in serum irEP (top) and underly- 
ing alterations in relative EPO production rates (bottom) in rats ex- 
posed to 3 different degrees of normobaric hypoxia. Serum irEP 
values are means t SE for 5 animals each, except a 12-h value for 7.5% 
O2 (n = 13). Relative production rates were calculated from increase in 
serum EPO levels, assuming a constant EPO half-life of 110 min (see 
RESULTS and Fig. 4). 
achieve peak serum levels of ~5,000 mu/ml (assuming a 
plasma volume of 3.93 ml/100 g body wt; see Ref. 29). 
This value even exceeds the levels of endogenous EPO 
under severe hypoxia (7.5%). Figure 3, bottom, gives the 
residual levels of the administered human EPO found 
24, 18, and 12 h after the injection in animals that were 
not exposed to hypoxia. Figure 3, top, demonstrates levels 
of endogenous rat irEP in animals exposed for 12 h to 
hypoxia (7.5% 02) either immediately after or 6 and 12 
h after the injection of rhEP0 or saline. It is obvious 
that the administration of rhEP0 at none of the three 
time points had any effect on endogenous EPO levels 
when compared with untreated controls that were si- 
multaneously exposed to hypoxia. 
To investigate whether the decline in serum EPO 
under continuous hypoxia was paralleled by changes in 
renal EPO mRNA content, Northern blot analysis for 
EPO mRNA was performed on kidney homogenates ob- 
tained from animals exposed to 7.5% O2 for 8 or 36 h. 
The result is illustrated in Fig. 4. Whereas no signal was 
detectable in normoxic animals, EPO mRNA increased 
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FIG. 3. Serum irEP levels in rats treated with 50 U recombinant 
human EPO at different time points before exposure to 12 h hypoxia 
(hatched bars) and in control animals injected with saline (open bars) 
(mean k SE, nos. in bars are numbers of animals). Residual levels of 
human EPO at time points corresponding to end of hypoxic exposure 
(bottom) were assessed in animals not exposed to hypoxia. Note differ- 
ent scales in both panels. Concentrations of human EPO (bottom) were 
measured against a standard curve consisting of human EPO (II-IRP) 
dissolved in normal rat serum. Concentrations of endogenous rat EPO 
(top) were measured against standard curves consisting of rat EPO 
with the 
added to 
concentration of residual human EPO respective average 
each standard point. 
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FIG. 4. Northern blot analysis of poly (A)’ RNA isolated from IW32 
(lane I), and from kidney extracts of normoxic rats (lane 2) and rats 
exposed to 7.5% Oz for 8 (lane 3) or 36 h (lane 4); (lane I: 5 ,.~g RNA, 
lanes 2-4: 20 fig RNA). Left: hybridization with an EPO probe. R$ht: 
rehybridization with an cu-tubulin probe after stripping the blot. 
was still detectable, but clearly reduced. Since EPO for- 
mation has been shown to be mainly determined by the 
amount of EPO mRNA (4, 27), this result indicates that 
the reduction in EPO levels is primarily due to dimin- 
ished hormone production. 
DISCUSSION 
The early kinetics of serum irEP under severe nor- 
mobaric hypoxia (7.5 and 9% 02) as determined in the 
present study (Fig. 2, top), are in accordance with pre- 
vious studies employing hypobaric (1, 5, 17, 20, 22, 24, 
26, 31) or also normobaric hypoxia (22). Although the 
reported time intervals after which peak serum levels 
were reached are variable, it appears to be a consistent 
finding that EPO titers do not remain at the elevated 
levels that are reached early upon hypoxia, but despite 
continued hypoxic exposure decline to values that are 
still above base line, but severalfold below peak concen- 
trations. 
The observation in the present investigation, that this 
decline in serum EPO is accompanied by a marked 
reduction of renal EPO mRNA content (Fig. 4), provides 
evidence that it is primarily due to a reduction in EPO 
production, rather than to enhanced hormone clearance 
or consumption. Interestingly, the pattern of EPO pro- 
duction rates, which were calculated under the assump- 
tion of a constant EPO disappearance rate (Fig. 2, bot- 
tom), resembles the time course of the amount of EPO 
extractable from kidneys under continuous hypoxia, as 
shown by Jelkmann (17) and Caro and Erslev (5). Peak 
levels of kidney EPO preceded peak concentrations of 
serum EPO, as did the calculated production rates. The 
fall in kidney EPO, which parallels the decline in serum 
levels, provides additional evidence for a reduction in 
EPO formation. 
Regarding the mechanisms by which the reduction in 
EPO production is mediated, we tested whether an in- 
crease in serum EPO due to exogenous administration 
of the hormone affects hypoxia-induced EPO formation. 
EPO was injected to achieve serum levels that even 
exceeded endogenous EPO levels preceding the decline 
in EPO production. Nevertheless, the endogenous EPO 
formation in response to subsequent hypoxic stimulation 
was unaffected (Fig. 3). This suggests that no feedback 
inhibition exists through the effect of circulating EPO 
on its production sites or target cells. 
In view of the marked increases in EPO production 
rates after the onset of hypoxia (Fig. 2, bottom) one 
might further consider an exhaustion of production ca- 
pacity. However, when the temporal patterns of EPO 
production rates under different hypoxic stimuli are com- 
pared (Fig. 2, bottom), it can be estimated from the areas 
under the curve that the decline in EPO production rate 
occurred independently of the amount of EPO produced. 
Thus, under 7.5% 02, twice as much EPO had been 
produced before production rates started to decline than 
under 9% Oz. 
Some investigators suggested a possible role of im- 
proved peripheral oxygenation through a rightward shift 
of the oxygen binding curve for the early decline in EPO 
production (8, 20, 26, 32). Direct studies on the effect of 
oxygen affinity of hemoglobin on EPO formation suggest, 
however, that its relative role decreases with increasing 
severity of hypoxia (19). In contrast, in our study the 
absolute and relative decline in EPO production rates as 
well as the rate of decline were more pronounced with 
increasing degrees of hypoxia (Fig. 2, bottom). Further- 
more, the quantitative effect of changes in oxygen affin- 
ity of hemoglobin is less than the observed decline seen 
in our investigation (19). 
Apart from systemic adaptations to hypoxia, the de- 
cline of EPO formation could also be related to altera- 
tions in renal hemodynamics. Under severe hypoxia a 
relative decrease in the glomerular filtration rate in 
comparison with renal blood flow has been reported in 
some studies (see Ref. 3). This might reduce the workload 
of the kidney and thereby decrease the ratio between 
oxygen consumption and oxygen supply, which is 
thought to determine EPO production rate. However, we 
have recently shown that the reduction of proximal tu- 
bular sodium reabsorption, required to inhibit EPO for- 
mation, amounts to -20% of the filtered load (11) and 
this exceeds changes observed under hypoxia. 
Finally, an adaptation to hypoxia could also occur at 
the cellular level of EPO formation, and might directly 
affect the transcription rate of the EPO gene, or alter- 
natively, decrease the stability of EPO mRNA, thereby 
reducing hormone production. Definite differentiation 
between these possibilities will await isolation of the 
renal cells producing EPO. 
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